Hologic, Inc. (NASDAQ:HOLX) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLXFree Report) by 3.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 131,955 shares of the medical equipment provider’s stock after selling 5,344 shares during the period. State of New Jersey Common Pension Fund D owned approximately 0.05% of Hologic worth $9,158,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Macquarie Group Ltd. grew its holdings in Hologic by 227.2% during the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock worth $435,485,000 after acquiring an additional 4,363,687 shares in the last quarter. Norges Bank acquired a new position in Hologic during the 4th quarter worth $175,900,000. Arrowstreet Capital Limited Partnership grew its holdings in Hologic by 110.6% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider’s stock worth $145,664,000 after acquiring an additional 995,854 shares in the last quarter. Prudential Financial Inc. grew its holdings in Hologic by 246.0% during the 1st quarter. Prudential Financial Inc. now owns 920,718 shares of the medical equipment provider’s stock worth $70,730,000 after acquiring an additional 654,628 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Hologic by 92.8% during the 1st quarter. Renaissance Technologies LLC now owns 1,300,461 shares of the medical equipment provider’s stock worth $99,901,000 after acquiring an additional 626,100 shares in the last quarter. 92.64% of the stock is owned by institutional investors and hedge funds.

Hologic Trading Up 0.0 %

Shares of NASDAQ:HOLX opened at $73.44 on Monday. The company has a market cap of $17.24 billion, a PE ratio of 34.81, a P/E/G ratio of 2.48 and a beta of 1.02. The company’s 50-day moving average price is $72.13 and its 200 day moving average price is $71.92. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLXGet Free Report) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. During the same period in the previous year, the firm earned $1.07 EPS. Hologic’s revenue was down 5.7% on a year-over-year basis. Sell-side analysts anticipate that Hologic, Inc. will post 4.02 earnings per share for the current year.

Insiders Place Their Bets

In other Hologic news, Director Scott T. Garrett sold 10,000 shares of the business’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $68.71, for a total transaction of $687,100.00. Following the sale, the director now directly owns 47,039 shares in the company, valued at approximately $3,232,049.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the transaction, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at $7,793,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Scott T. Garrett sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $68.71, for a total transaction of $687,100.00. Following the transaction, the director now directly owns 47,039 shares in the company, valued at $3,232,049.69. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,440 shares of company stock worth $2,346,475. 1.75% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on HOLX shares. Morgan Stanley decreased their price objective on shares of Hologic from $86.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, November 13th. Needham & Company LLC lifted their price target on shares of Hologic from $83.00 to $90.00 and gave the company a “buy” rating in a report on Friday, February 2nd. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, January 18th. Raymond James lifted their price target on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, UBS Group lifted their price target on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $86.89.

Read Our Latest Stock Analysis on Hologic

Hologic Company Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Read More

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.